Interferon-γ 1b in idiopathic pulmonary fibrosis: What we know and what must we learn

American Journal of Respiratory and Critical Care Medicine

Volumn 170, Issue 2, 2004, Pages 107-108

  Dauber, James H ^a   Gibson, Kevin F ^a   Kaminski, Naftali ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA1B INTERFERON;

ANGIOGENESIS; ANTIMICROBIAL ACTIVITY; DISEASE COURSE; EDITORIAL; EXTRACELLULAR MATRIX; GENE EXPRESSION; HUMAN; LUNG FIBROSIS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; SURVIVAL; TRANSBRONCHIAL BIOPSY;

BIOLOGICAL MARKERS; CHEMOKINES, CXC; HUMANS; INTERFERON-GAMMA, RECOMBINANT; LUNG; PROGNOSIS; PULMONARY FIBROSIS; TREATMENT OUTCOME;

EID: 3142668885     PISSN: 00030805     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (14)

1. Ziesche R, Hofbauer E, Wittmann K, Petkov V, Block LH. A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis. N Engl J Med 1999;341:1264-1269.
2. Ulloa L, Doody J, Massague J. Inhibition of transforming growth factor-beta/SMAD signaling by the interferon-gamma/STAT pathway. Nature 1999;397:710-713.
3. Strieter RM, Starko KM, Enelow RI, Not I, Valentine VG. Effects of interferon-γ-1b on biomarker expression in idiopathic pulmonary fibrosis patients. Am J Respir Crit Care Med 2004;170:133-140.
4. Raghu G, Brown KK, Bradford WZ, Starko K, Noble PW, Schwartz DA, King, Jr TE. A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med 2004;350:125-133.
5. Cosgrove GP, Brown KK, Cool CD, Geraci MW, Schwartz MI, Worthen GS. Angiogenesis in pulmonary pibrosis [abstract]. Am J Respir Crit Care Med 2002;165:A172.
6. Zuo F, Kaminski N, Eugui E, Allard J, Yakhini Z, Ben-Dor A, Lollini L, Morris D, Kim Y, DeLustro B, Sheppard D, Pardo A, Selman M, Heller RA. Gene expression analysis reveals matrilysin as a key regulator of pulmonary fibrosis in mice and humans. Proc Natl Acad Sci USA 2002;99:6292-6297.
7. Keane M, Belperio JA, Arenberg DA, Burdick MD, Xu ZJ, Xue YY, Streiter RM. IFN-gamma-inducible protein-10 attenuates bleomycin-induced pulmonary fibrosis via inhibition of angiogenesis. J Immunol 1999;163:5686-5692.
8. Brewer GJ, Ullenbruch MR, Dick R, Olivarez L, Phan SH. Tetrathiomolybdate therapy protects against bleomycin-induced pulmonary fibrosis in mice. J Lab Clin Med 2003;141:210-216.
9. Ebina M, Shimizukawa M, Shibata N, Kimura Y, Suzuki T, Endo M, Sasano H, Kondo T, Nukiwa T. Heterogeneous increase of CD34-positive alveolar capillaries in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. published ahead of print on January 30, 2004 as doi:10.1164/rccm.200308-1111OC
10. Kao J, Kobashigawa J, Fishbein MC, MacLellan WR, Burdick MD, Belperio JA, Streiter RM. Elevated serum levels of the CXCR3 chemokine ITAC are associated with the development of transplant coronary artery disease. Circulation 2003;107:1958-1961.
11. Selman M, Thannickal VJ, Pardo A, Zisman DA, Martinez FJ, Lynch JP III. Idiopathic pulmonary fibrosis: pathogenesis and therapeutic approaches. Drugs 2004;64:405-430.
12. Crystal RG, Bitterman PB, Mossman B, Schwarz MI, Sheppard D, Almasy L, Chapman HA, Friedman SL, King TE Jr, Leinwand LA, et al. Future research directions in idiopathic pulmonary fibrosis: summary of a National Heart, Lung, and Blood Institute working group. Am J Respir Crit Care Med 2002;166:236-246.
13. Achiro A, Gurevich M, Friedman N, Kaminski N, Mandel M. Blood transcriptional signatures of multiple sclerosis: unique gene expression of disease activity. Ann Neurol 2004;55:410-417.
14. Koike F, Satoh J, Miyake S, Yamamoto T, Kawai M, Kikuchi S, Nomura K, Yokoyama K, Ota K, Kanda T, et al. Microarray analysis identifies interferon beta-regulated genes in multiple sclerosis. J Neuroimmunol 2003;139:109-118.